EphA2-FAK-siRNA-DOPC exerted significant tumor growth reduction (90%) in comparison to EphA2-siRNA-DOPC (67%) and FAK-siRNA-DOPC (62%) in HeyA8 model. Here, PTK2 is linked to neoplasm.